INTRODUCTION
Patients and physicians may have different perspectives on medical outcomes and what may constitute a reasonable risk to achieve those outcomes (1) (2) (3) . In light of these differences, the Institute of Medicine recommends the inclusion of patients in guideline development projects to help ensure adequate consideration of patients' perspectives (4) . A small number of patients on a panel may, however, be unrepresentative and a method to ensure representative patient input for a guideline development project remains unresolved (5).
Options to incorporate patients' values and preferences might include focus groups or systematic reviews of formal studies of patients' values and preferences that can also inform Guideline Panels on what is important to patients.
Patients have contributed their perspectives to multiple projects to develop treatment recommendations and guidelines. Previous work has further demonstrated that when presented with high-quality evidence, panels composed entirely of patients may reach similar conclusions as do panels of physicians (5) . Patients' values and preferences are particularly important when the evidence quality is not high or when trade-offs between benefits and harms are closely balanced (6) . Recommendations in these situations may be characterized as value and preference sensitive (7) (8) (9) (10) . In this setting, the patients' perspective may have a particularly strong influence on the direction and strength of the recommendations.
The American College of Rheumatology (ACR) and the American Association of Hip and Knee Surgeons (AAHKS) proposed the development of a guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA) (11) . No guideline has been published since the introduction of many of the current antirheumatic medications, and practice patterns vary widely. Observations that patients with rheumatic diseases were at higher risk for adverse events, including infection, after THA and TKA compared to patients with osteoarthritis (odds ratios/risk ratios for infection of 1.8-4.8) (12) and that most patients with rheumatic diseases undergoing THA and TKA were receiving potent immunosuppressant antirheumatic medications at the time of surgery, suggested that perioperative medication management decisions might contribute to the frequency of adverse outcomes. The aim of the guideline was to help minimize adverse events including perioperative infections and disease flares. The topics addressed by the guideline included: 1) Should antirheumatic medications be withheld prior to elective THA/TKA? 2) If they are withheld, when should they be stopped? 3) If withheld, when should they be restarted after surgery? 4) In patients receiving glucocorticoids, what dose should be administered at the time of surgery?
For the guideline, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used as specified in the ACR guideline development process (available at www.rheumatology.org/Practice-Quality/ Clinical-Support/Clinical-Practice-Guidelines). Using this method, the clinically relevant questions are formatted into PICO (population/intervention/comparator/outcomes) questions that identify the specific elements of the relevant clinical question and that inform a systematic literature review (13, 14) . The Guideline Panel reviews the relevant evidence to assess the balance between the potential benefit of the intervention (withholding medication may decrease infection) and the potential for harm (withholding medication may increase flares of disease) prior to developing practice recommendations.
GRADE, an internationally recognized method, rates the strength of the recommendation as either strong or conditional based largely on the quality of the available evidence informing the recommendations, but also on the presumed variability of patient values and preferences. A strong recommendation indicates that all or almost all informed patients would select that treatment option. A conditional recommendation indicates that the evidence base is not robust, the balance of benefit and harm is not as certain, and the optimal clinical decision requires the consideration of individual patient values and preferences. Conditional recommendations are warranted when the majority (defined as .50%) of informed patients would choose to follow a conditional recommendation, but others would not (8, 15, 16) .
For this guideline, the crucial trade-off was between perioperative infections (ranging in severity from nonserious to serious) and the risk of disease flares, which are common when medications are discontinued. An ACR/AAHKS Panel supported by ACR staff and consisting of 6 orthopedists, 5 rheumatologists, an infectious disease expert, a systemic lupus erythematosus (SLE) expert, 2 patient representatives with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), 2 rheumatology methodologists, and an additional expert in GRADE methodology voted on the final recommendations. Our aim is to report on the significant contribution of the Patient Panel, which was convened for the perioperative medication management guideline, and to describe a successful model for increased integration of the patients' perspective in guideline development. Scope of the project. The patients were informed of the rationale and the scope of the project, and the assumptions of the project were presented. They were informed that the
METHODS

Significance & Innovations
This guideline demonstrates the clear benefit of patient input informing the strength and direction of the recommendations.
Patient values and preferences can play a critical role when the quality of the evidence base is low or when there are important trade-offs between benefits and harms.
The patients' recommendations were guided by their strong and unanimous preference for minimizing risk of infections over minimizing risk of disease flares.
Formally determining patient values and preferences led to patient-centric recommendations that were ultimately congruent for both Patient and Voting Panels. goal was to provide guidance for perioperative antirheumatic medication management even when evidence was sparse, to provide guidance for clinicians and patients, to optimize THA and TKA outcomes, and to minimize adverse outcomes. Routine preoperative medical assessment and adverse events of concern, including venous thromboembolism or cardiac events, were not within the scope of this guideline and were covered by other guidelines (17, 18) . Medications and diseases were initially to be considered separately, but limitations in the available literature led us to group them together, except for questions pertaining to SLE.
This guideline addresses only those perioperative events that could be attributable to the disease-specific antirheumatic therapy. Although outcomes that included hip dislocation and 90-day hospital readmission were sought in the literature, literature was sparse and these complications could not be directly linked to the medication management decisions. Therefore, the outcomes of interest were limited to infections (including nonserious and serious infections involving either the surgical site or a remote site) versus flares of rheumatic disease.
The values and preferences of the patients were elicited to give weight to the balance between benefits and harms. The patients were specifically queried on the relative importance of infections, infrequent events possibly linked to continued immunosuppressant disease-modifying antirheumatic drug and biologic agent therapy, compared to the importance of flares of disease that occur frequently after THA and TKA and may be linked to withholding the medications. The Patient Panel was encouraged to consider their personal experiences relevant to the questions and judge the importance of the outcomes accordingly.
RESULTS
Moving from evidence to recommendations. The Patient Panel consisted of 11 adults with RA or JIA, all of whom had undergone THA or TKA (range of 1 to 8 joints replaced per patient). Only 1 patient reported experiencing a prosthetic joint infection. The mean age of participants was 47 years (range 23-71 years) and the mean disease duration was 26 years (range 8-42 years). Of these patients, 10 were female and 1 was of a minority race/ethnicity.
The Patient Panel reviewed the evidence synthesized by the guideline Literature Review Panel as each PICO question was discussed (the same information that the ACR/AAHKS Voting Panel considered the following day) ( Table 1 ). The patients addressed the PICO questions that informed the guideline project, reviewed and discussed the data, and formally voted anonymously on the drafted recommendations that were formulated from the PICO questions. The methods used were the same between the Patient and Voting Panels (Figure 1 ). When consensus was not reached, there was further clarifying discussion and the votes were repeated until an 80% or higher consensus was achieved. The Patient Panel facilitators questioned the patients at length to better understand this preference. The patients felt that flares represented a "known risk" that they could control and that in particular can usually be treated. In contrast to the predictability of flares, the patients perceived that there is no "average" infection-only very bad ones, with a risk of much worse outcomes than flares (e.g., permanent loss of prosthesis, extremity amputation, prolonged hospitalization, dependence and disability, and death).
The patients viewed enduring the perioperative period as a "job" in which their task was to focus on the eventual positive outcomes of better mobility and less pain, and "dealing with a flare was simply part of the hard work." One patient said, "I always assume I will be in a flare when I enter surgery and for a while when I come out, but I'm afraid of infection." Others agreed, "I always expect to flare." They considered the burden of infection to be much larger than the burden of flares, as their lives were already set up to deal with flares. Although flares were perceived as difficult, patients were aware that an infection could postpone recovery and/or introduce other health issues, which they felt was unacceptable because it would delay achieving the positive outcomes they sought. One patient noted that, "you can die from an infection, but you won't die from a flare," and that, "infections usually mess up [her] life for months on end . . . RaƟonale: While both paƟents and physicians agreed that all biologic agents should be withheld prior to surgery and agreed that the surgery should be Ɵmed to the end of the dosing cycle to minimize persistent immunosuppression, the paƟents stressed individualizing the recommendaƟons for each paƟent. The paƟents were comfortable with the indirect/ lowquality evidence presented, while the 1 discordant vote among the expert panel was due to low-quality evidence. The paƟents were reluctant to vote on the clinical scenario related to paƟents with SLE, as there were no paƟents with SLE on the PaƟent Panel. as months of antibiotics and other things related to infections messes up a patient's life." Moreover, while they felt they could manage flares at home, the consequences of infections (including the frequent occurrence of associated flares) would likely require prolonged hospitalization and a stay in a rehabilitation center. Our study had several limitations. The Patient Panel was chosen by 2 patient advocacy organizations to be representative of patients with rheumatic conditions. However, it is possible that despite our effort to have an adequate representation of men, minority races/ethnicities, and patients with lower income/socioeconomic status, this Panel may not be representative of all patients in the US. In particular, the panelists were hesitant to make recommendations for patients with SLE because there were no patients with SLE on the Patient Panel. Patient experience ranged from 1 to 8 joint replacements, which may have influenced their values and preferences and their perception of risks and benefits. However, each patient on the Panel had had at least 1 joint replacement, and therefore the Panel had substantial experience with the perioperative period and antirheumatic medication use during that period.
DISCUSSION
Although patients have previously reached concordant votes with Physician Panels and have developed recommendations based on similar evidence as expert Voting Panels, patients have previously withheld votes when the evidence was not high quality (5) . In this project, patients voted on all the recommendations despite the lack of high-quality evidence, guided by their strong preference for minimizing the risk of infection over risk of flares. As there were no patients with SLE in this group, the Patient Panel expressed discomfort making assumptions about the values and preferences of patients with SLE, but voted based on their understanding of severe SLE contrasted with SLE that was not severe. This suggests that patients were comfortable with their experience contributing to an evidence base that would shape practice guidelines, similar in fashion to the consideration of experience taken by Expert/Physician Panels.
Although physician and patient values and preferences may differ and at times be opposed, patient values and preferences typically shape and inform physician advice. In this study, we have demonstrated the importance of formally determining the values and preferences of the patients, leading to patient-centric recommendations that were ultimately congruent for both groups, and which may facilitate implementation (19) (20) (21) . However, it should be noted that we do not know whether the Voting Panel would have made the same recommendation without the input of the Patient Panel.
There is no consensus among guideline developers on how best to incorporate patient values and preferences into guidelines. The ACR has previously involved 1 to 2 patients as members of guideline Voting Panels, but has received feedback that these patients do not always feel empowered to speak up in that setting, nor do they feel that their perspectives and experiences are uniquely valued. Moreover, the values of these 1 or 2 individuals may not be representative of the wider community. Therefore, the ACR piloted the idea and logistics of including a separate Patient Panel in a guideline project, but has previously asked patients to provide input on recommendations only when the evidence is high quality. For this ACR/AAHKS guideline we went a step further, asking the patients to consider and vote on all preliminarily drafted recommendations, even though all of the evidence was indirect or of moderate to low quality.
In summary, in this project, the patients' preferences were elicited prior to the decisions of the ACR/AAHKS Voting Panel, and presented to the Voting Panel to consider as the final recommendations were determined. Although the optimal method for incorporating patients' preferences into clinical practice guidelines has not been determined, this guideline demonstrated the clear benefit of patient input in the presence of a relatively weak evidence base in shaping the strength and direction of the decisions made by a Physician Voting Panel. The findings of this project support the formal incorporation of information elicited from separately convened Patient Panels into clinical practice guidelines.
